Evidence map›Paper›PMID 24916348›Full record

ArticleHNO2014

[Regulatory T cells and NK cells in cancer patients].

C Bergmann

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in HNO, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

C BergmannKlinik für Hals-Nasen-Ohren-Heilkunde, Universitätsklinikum Essen (AöR), Hufelandstr. 55, 45147, Essen, Deutschland, christoph.bergmann@uk-essen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NK cells represent the cells of the immune system most effective for eradication of infected or neoplastic cells. Regulatory T cells and the two main subgroups thereof-the naturally occurring nTregs and the tumor-associated induced Tregs (iTregs)-play an important role in the antitumor immune response in cancer patients. The current study explores the intercellular interactions of these groups of cells in tumor patients, particularly in head and neck cancer. Critical interactions between these cells and the cancer cells could be observed in extensive experimental analyses. Firstly, we generated tumor-associated iTregs in a specific human culture. Subsequently, various phenotypic and functional relationships between these cells, nTregs, NK cells and tumor cells were analyzed in an autologous system. Although the activity of naive NK cells was enhanced by iTregs in the presence of tumor cells, the cytotoxic function of NK cells activated by interleukin-2 was markedly inhibited by iTregs and nTregs. Our group was able to document new insights into the complex regulation of human NK cells and regulatory T cells in the tumor microenvironment. These new insights may be of relevance for an improved understanding of the antitumor immune response and the development of immunotherapeutic strategies.

Indexed as

Cell CommunicationHead and Neck NeoplasmsHumansImmunity, InnateKiller Cells, NaturalModels, ImmunologicalT-Lymphocytes, Regulatory

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.